聚焦审评审批新政,迎接药物研发创新的最好时代——《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》专家解读  

Focus on New Polices on Drug Review and Approval, and Embrace the Best Era of Drug Development Innovation:Expert Interpretations of "Opinions on Deepening the Reform of Drug Review and Approval System and Encouraging Innovation in Pharmaceutical Products a

机构地区：[1]<药学进展>编辑部

出　　处：《药学进展》2017年第10期775-782,共8页Progress in Pharmaceutical Sciences

摘　　要：针对中共中央办公厅、国务院办公厅于2017年10月8日联合印发并实施的《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》(以下简称《意见》),征集《药学进展》编委中来自医药企业、科研单位、政府机构、CRO、临床研究机构等不同领域的专家的真知灼见。旨在从多个角度对《意见》进行深入分析和专业解读,加深行业人士对《意见》的理解。In response to ＂Opinons on Deepening the Reform of Drug Review and Approval System and Encouraging Innovation in Pharmaceutical Products and Medical Apparatus＂ which was approved by General Office of the CPC Central Committee and General Office of the State Council on 8 th October, 2017, a series of profound knowledge and penetrating insight on this document were collected from members of Editorial Board of Progress in Pharmaceutical Sciences who are also experts of different fields, including pharmaceutical enterprise, scientific research institution, government department, CRO and clincal trial institution. It was aimed at bringing in-depth analyses and interpretations, and sharpening the understandings of this document by insiders of pharmaceutical industry.

关 键 词：药品审评 审批制度 药品研发 

分 类 号：R951[医药卫生—药学]